CircDCAF8 Promotes the Progression of Hepatocellular Carcinoma Through MiR-217/NAP1L1 Axis, and Induces Angiogenesis and Regorafenib Resistance Via Exosome-mediated Transfer

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 May 30

PMID 38816735

Authors

Jiahao Gong

Guoyong Han

Zhiqiang Chen

Yinqi Zhang

Bin Xu

Chao Xu

Wen Gao

Jindao Wu

Affiliations

Soon will be listed here.

Abstract

Background: Circular RNAs (circRNAs), which are a new type of single-stranded circular RNA, have significant involvement in progression of many diseases, including tumors. Currently, multiple circRNAs have been identified in hepatocellular carcinoma (HCC). Our study aims to investigate the function and mechanism of circDCAF8 in HCC.

Methods: The expression of circDCAF8 (hsa_circ_0014879) in HCC and para-carcinoma tissue samples was determined using quantitative real-time polymerase chain reaction (qRT-PCR). The biological function of circDCAF8 in HCC was confirmed by experiments conducted both in vitro and in vivo. And the relationship between circDCAF8, miR-217 and NAP1L1 was predicted by database and verified using qRT-PCR, RNA-binding protein immunoprecipitation (RIP) and dual-luciferase reporter assays. Exosomes isolated from HCC cells were utilized to assess the connection of exosomal circDCAF8 with HCC angiogenesis and regorafenib resistance.

Results: CircDCAF8 is upregulated in HCC tissues and cell lines, and is linked to an unfavourable prognosis for HCC patients. Functionally, circDCAF8 was proved to facilitate proliferation, migration, invasion and Epithelial-Mesenchymal Transformation (EMT) in HCC cells. Animal examinations also validated the tumor-promoting characteristics of circDCAF8 on HCC. Besides, exosomal circDCAF8 promoted angiogenesis in HUVECs. Mechanistically, circDCAF8 interacted with miR-217 and NAP1L1 was a downstream protein of miR-217. CircDCAF8 promoted NAP1L1 expression by sponging miR-217. In addition, exosomes may transfer circDCAF8 from regorafenib-resistant HCC cells to sensitive cells, where it would confer a resistant phenotype.

Conclusion: CircDCAF8 facilitates HCC proliferation and metastasis via the miR-217/NAP1L1 axis. Meanwhile, circDCAF8 can promote angiogenesis and drive resistance to regorafenib, making it a viable therapeutic target for HCC patients.

Citing Articles

Role of circular RNAs in cancer therapy resistance.

Liu W, Niu J, Huo Y, Zhang L, Han L, Zhang N Mol Cancer. 2025; 24(1):55.

PMID: 39994791 PMC: 11854110. DOI: 10.1186/s12943-025-02254-5.

Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance.

Gawi Ermi A, Sarkar D Cancers (Basel). 2024; 16(23).

PMID: 39682130 PMC: 11640171. DOI: 10.3390/cancers16233944.

Exosomal circular RNAs in tumor microenvironment: An emphasis on signaling pathways and clinical opportunities.

Li J, Zhou W, Wang H, Huang M, Deng H MedComm (2020). 2024; 5(12):e70019.

PMID: 39584047 PMC: 11586091. DOI: 10.1002/mco2.70019.

References

Huang A, Yang X, Chung W, Dennison A, Zhou J . Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1):146. PMC: 7419547. DOI: 10.1038/s41392-020-00264-x. View

Heo Y, Syed Y . Regorafenib: A Review in Hepatocellular Carcinoma. Drugs. 2018; 78(9):951-958. DOI: 10.1007/s40265-018-0932-4. View

Xu J, Wan Z, Tang M, Lin Z, Jiang S, Ji L . N-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling. Mol Cancer. 2020; 19(1):163. PMC: 7681956. DOI: 10.1186/s12943-020-01281-8. View

Huang M, Lin Y, Wang C, Deng L, Chen M, Assaraf Y . New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects. Drug Resist Updat. 2022; 64:100849. DOI: 10.1016/j.drup.2022.100849. View

Wong C, Tsang F, Ng I . Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018; 15(3):137-151. DOI: 10.1038/nrgastro.2017.169. View

Huang Y, Yang X, Lu Y, Zhao Y, Meng R, Zhang S . UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance. Cell Death Differ. 2020; 28(2):671-684. PMC: 7862231. DOI: 10.1038/s41418-020-00616-8. View

Li H, Liu Y, Cheng C, Wu Y, Liang S, Wu L . UBE2O reduces the effectiveness of interferon-α via degradation of IFIT3 in hepatocellular carcinoma. Cell Death Dis. 2023; 14(12):854. PMC: 10740027. DOI: 10.1038/s41419-023-06369-9. View

Hu Z, Chen G, Zhao Y, Gao H, Li L, Yin Y . Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Mol Cancer. 2023; 22(1):55. PMC: 10024440. DOI: 10.1186/s12943-023-01759-1. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

10.

Wang M, Yu F, Li P . Circular RNAs: Characteristics, Function and Clinical Significance in Hepatocellular Carcinoma. Cancers (Basel). 2018; 10(8). PMC: 6116001. DOI: 10.3390/cancers10080258. View

11.

Chen Z, Gao W, Pu L, Zhang L, Han G, Zuo X . PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1. Hepatology. 2018; 68(3):994-1009. DOI: 10.1002/hep.29890. View

12.

Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

13.

Dong Z, Ke A, Li T, Cai J, Yang Y, Zhou W . CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity. Mol Cancer. 2021; 20(1):75. PMC: 8117652. DOI: 10.1186/s12943-021-01361-3. View

14.

Chen X, Zhang S, Liu C, Li G, Lu S, Wang Y . UBE2O Promotes Progression and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. Onco Targets Ther. 2020; 13:6191-6202. PMC: 7334014. DOI: 10.2147/OTT.S253861. View

15.

Schimmack S, Taylor A, Lawrence B, Alaimo D, Schmitz-Winnenthal H, Buchler M . A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases. Epigenetics Chromatin. 2014; 7:15. PMC: 4112619. DOI: 10.1186/1756-8935-7-15. View

16.

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

17.

Vicens Q, Westhof E . Biogenesis of Circular RNAs. Cell. 2014; 159(1):13-14. DOI: 10.1016/j.cell.2014.09.005. View

18.

Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J . Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015; 25(8):981-4. PMC: 4528056. DOI: 10.1038/cr.2015.82. View

19.

Personeni N, Pressiani T, Rimassa L . Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma. 2019; 6:31-39. PMC: 6362912. DOI: 10.2147/JHC.S168953. View

20.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View